DPP4 and diabetes mellitus: From a pharmacological perspective regarding weight loss, there is little evidence of the benefit in reducing the risk of AF with medications used in diabetes that induce significant weight loss and improve insulin sensitivity, such as glucagon-like peptide -1 receptor agonists, sodium-glucose transport protein 2 (SGLT2), and dipeptidyl peptidase-4 (DPP-4) inhibitors [23].